Infection and drug resistance · 2025
Formulation and Evaluation of a Licorice-Resveratrol Lollipop for Targeting Streptococcus mutans Biofilm and Antimicrobial Resistance.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Patil Sandip, Powar Gauri Suresh, Harale Swapnil, Galatage Sunil T, Liu Sixi, Lopes Bruno Silvester, Sharma Devender Kumar, Patil Abhinandan Ravsaheb, Wen Feiqiu
Аннотация
BACKGROUND: Streptococcus mutans is a key pathogen in dental caries, and the development of novel antimicrobial formulations is crucial to combat its resistance. This study aimed to evaluate a licorice-resveratrol medicated lollipop formulation (LRML) for its antimicrobial and anti-biofilm activity against S. mutans.
METHODS: The LRML was developed using a heating and congealing method, incorporating licorice extract (5% w/w) and resveratrol (2% w/w) in a sucrose-based matrix. The physicochemical properties of the formulation, including hardness, drug content uniformity, moisture content, and dissolution profile, were evaluated. The antimicrobial activity was assessed through Minimum Inhibitory Concentration (MIC), Minimum Bactericidal Concentration (MBC), and time-kill assays. Anti-biofilm activity was evaluated using a crystal violet assay. The stability of the formulation was determined under accelerated conditions.
RESULTS: The LRML formulation showed efficient drug release, with formulation number LRML-7 demonstrating 96.87% release within 45 minutes. The antimicrobial tests revealed significant bactericidal effects against S. mutans at concentrations above 0.2 µg/mL, with a notable reduction in bacterial growth in time-kill assays. The formulation also demonstrated substantial inhibition of biofilm formation at both MIC and Minimum Bactericidal Concentration (MBC) levels. Stability studies confirmed that the formulation retained its physicochemical properties over three months.
CONCLUSION: The LRML exhibited promising antimicrobial and anti-biofilm activities against S. mutans, suggesting its potential as a novel therapeutic option for managing dental infections. Further clinical studies are required to optimize the formulation's efficacy and clinical applicability.
METHODS: The LRML was developed using a heating and congealing method, incorporating licorice extract (5% w/w) and resveratrol (2% w/w) in a sucrose-based matrix. The physicochemical properties of the formulation, including hardness, drug content uniformity, moisture content, and dissolution profile, were evaluated. The antimicrobial activity was assessed through Minimum Inhibitory Concentration (MIC), Minimum Bactericidal Concentration (MBC), and time-kill assays. Anti-biofilm activity was evaluated using a crystal violet assay. The stability of the formulation was determined under accelerated conditions.
RESULTS: The LRML formulation showed efficient drug release, with formulation number LRML-7 demonstrating 96.87% release within 45 minutes. The antimicrobial tests revealed significant bactericidal effects against S. mutans at concentrations above 0.2 µg/mL, with a notable reduction in bacterial growth in time-kill assays. The formulation also demonstrated substantial inhibition of biofilm formation at both MIC and Minimum Bactericidal Concentration (MBC) levels. Stability studies confirmed that the formulation retained its physicochemical properties over three months.
CONCLUSION: The LRML exhibited promising antimicrobial and anti-biofilm activities against S. mutans, suggesting its potential as a novel therapeutic option for managing dental infections. Further clinical studies are required to optimize the formulation's efficacy and clinical applicability.